PL386429A1 - New 4,6-disubstituted 2-(4-methylpiperazine-1-yl) pyridine derivatives and farmaceuticals containing those compounds, and their application - Google Patents

New 4,6-disubstituted 2-(4-methylpiperazine-1-yl) pyridine derivatives and farmaceuticals containing those compounds, and their application

Info

Publication number
PL386429A1
PL386429A1 PL386429A PL38642908A PL386429A1 PL 386429 A1 PL386429 A1 PL 386429A1 PL 386429 A PL386429 A PL 386429A PL 38642908 A PL38642908 A PL 38642908A PL 386429 A1 PL386429 A1 PL 386429A1
Authority
PL
Poland
Prior art keywords
farmaceuticals
methylpiperazine
disubstituted
new
application
Prior art date
Application number
PL386429A
Other languages
Polish (pl)
Inventor
Maria Paluchowska
Andrzej Bojarski
Anna Wesołowska
Original Assignee
Instytut Farmakologii Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Farmakologii Polskiej Akademii Nauk filed Critical Instytut Farmakologii Polskiej Akademii Nauk
Priority to PL386429A priority Critical patent/PL386429A1/en
Priority to PCT/PL2009/000098 priority patent/WO2010053388A1/en
Publication of PL386429A1 publication Critical patent/PL386429A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL386429A 2008-11-04 2008-11-04 New 4,6-disubstituted 2-(4-methylpiperazine-1-yl) pyridine derivatives and farmaceuticals containing those compounds, and their application PL386429A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL386429A PL386429A1 (en) 2008-11-04 2008-11-04 New 4,6-disubstituted 2-(4-methylpiperazine-1-yl) pyridine derivatives and farmaceuticals containing those compounds, and their application
PCT/PL2009/000098 WO2010053388A1 (en) 2008-11-04 2009-11-03 New 4,6-disubstituted 2-(4-methylpiperazin-1-yl)pyridine derivatives, a process for their preparation, pharmaceutical composition containing these compounds, their use, a method for modulating monoaminergic receptor activity and a monoaminergic receptor modulating agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL386429A PL386429A1 (en) 2008-11-04 2008-11-04 New 4,6-disubstituted 2-(4-methylpiperazine-1-yl) pyridine derivatives and farmaceuticals containing those compounds, and their application

Publications (1)

Publication Number Publication Date
PL386429A1 true PL386429A1 (en) 2010-05-10

Family

ID=41508102

Family Applications (1)

Application Number Title Priority Date Filing Date
PL386429A PL386429A1 (en) 2008-11-04 2008-11-04 New 4,6-disubstituted 2-(4-methylpiperazine-1-yl) pyridine derivatives and farmaceuticals containing those compounds, and their application

Country Status (2)

Country Link
PL (1) PL386429A1 (en)
WO (1) WO2010053388A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160009697A1 (en) * 2013-02-21 2016-01-14 Selvita S.A. Pyridine derivatives as 5-ht6 receptor antagonists
KR102014335B1 (en) * 2017-12-01 2019-08-26 한국과학기술연구원 Arylpyrazolylpiperazine or diazepane derivatives acting as 5-HT7 receptor ligands and pharmaceutical composition for treating or preventing central nervous system diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005316671A1 (en) * 2004-12-13 2006-06-22 Arena Pharmaceuticals, Inc. N-biaryl and N-arylheteroaryl 2-substituted piperazine derivatives as modulators of the 5HT2C receptor useful for the treatment of disorders related thereto
US8022209B2 (en) * 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor

Also Published As

Publication number Publication date
WO2010053388A1 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
IL200431A0 (en) 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2 -receptor modulators
SI2217578T1 (en) Š1,2,4ćtriazološ1,5-aćpyridine and š1,2,4ćtriazološ1,5-cćpyrimidine compounds and their use
EP2200573A4 (en) Resveratrol ferulate compounds, compositions containing the compounds, and methods of using the same
PL2000123T3 (en) Stable, low viscosity cosmetic compounds containing esterquat and/or dialkylquat
IL201973A0 (en) 3,3-spiroindolinone derivatives
IL214961A0 (en) Pyridine derivative compounds, compositions comprising the same and uses thereof
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
ZA201001221B (en) 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
IL202883A (en) N-{2- (hetaryl) aryl} arylsulfonamides and n- {2-(hetaryl)hetaryl} arylsulfonamides, pharmaceutical compositions comprising the same and uses thereof
IL202826A0 (en) New compounds and their uses 708
IL206127A0 (en) Azolylmethyloxiranes, use thereof and agents containing the same
ZA201001797B (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
IL205536A0 (en) Modulation of factor 7 expression
EP2150111A4 (en) Substituted 1,3-dioxanes useful as ppar modulators
PL2139334T3 (en) 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof
IL207201A0 (en) Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof
IL211674A0 (en) 3-amino-indazole or 3-amino-4,5,6,7- tetrahydro-indazole derivatives
HK1140106A1 (en) Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof -2-
HK1207319A1 (en) 3,6-disubstituted xanthylium salts 36-
HRP20171742T1 (en) Composition of 2,4,6-trifluoro-n-6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
IL205666A0 (en) Pyridine compounds
EP2358702A4 (en) Piperidine compounds, pharmaceutical composition comprising the same and its use
PL381862A1 (en) Application of pyridine compounds and the manner of treatment
SI2188258T1 (en) Substituted nicotinamide compounds and the use thereof in pharmaceutical products
IL201015A0 (en) New compounds and their uses 707

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)